Clinical Trials Browser

Phase 1 × Leukemia, Plasma Cell × liposomal doxorubicin × Clear all

NCT03591744 2018-12-19

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Phase 1 Withdrawn

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell